Achilles Therapeutics Financials
| ACHL Stock | USD 1.08 0.01 0.93% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.18 | 8.5687 |
|
|
Investors should never underestimate Achilles Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Achilles Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Achilles Therapeutics PLC.
Net Income |
|
Achilles | Select Account or Indicator |
Understanding current and past Achilles Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Achilles Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Achilles Therapeutics' assets may result in an increase in income on the income statement.
Achilles Therapeutics Stock Summary
Achilles Therapeutics competes with Tff Pharmaceuticals, Eliem Therapeutics, Inhibrx, and Enliven Therapeutics. Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company was founded in 2016 and is headquartered in London, the United Kingdom. Achilles Therapeutics is traded on NASDAQ Exchange in the United States.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US00449L1026 |
| CUSIP | 00449L102 |
| Location | United Kingdom |
| Business Address | 245 Hammersmith Road, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.achillestx.com |
| Phone | 44 20 8154 4600 |
| Currency | USD - US Dollar |
Achilles Therapeutics Key Financial Ratios
| Return On Equity | -0.44 | ||||
| EBITDA | (70.44 M) | ||||
| Net Income | (69.94 M) | ||||
| Cash Per Share | 4.94 X | ||||
| Debt To Equity | 0.04 % |
Achilles Therapeutics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Current Liab | 681K | 6.6M | 10.9M | 8.3M | 7.8M | 6.3M | |
| Net Tangible Assets | 101.3M | 189.2M | 289.5M | 197.0M | 226.6M | 173.7M | |
| Retained Earnings | (24.8M) | (58.0M) | (119.1M) | (190.3M) | (260.0M) | (247.0M) | |
| Accounts Payable | 902K | 6.3M | 3.7M | 5.2M | 5.6M | 4.0M | |
| Net Receivables | 4.5M | 7.3M | 11.2M | 16.0M | 10.4M | 9.5M | |
| Other Current Assets | 477K | 2.6M | 7.3M | 7.2M | 3.7M | 4.0M | |
| Total Current Assets | 103.1M | 187.8M | 284.7M | 196.6M | 145.6M | 170.7M |
Achilles Therapeutics Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 215K | 531K | 3.1M | 7.3M | 8.4M | 8.8M | |
| Ebit | (13.8M) | (33.7M) | (61.1M) | (82.1M) | (75.2M) | (71.4M) |
Achilles Therapeutics Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 86.9M | 80.3M | 88.5M | (93.0M) | (41.8M) | (39.7M) | |
| Depreciation | 302K | 772K | 3.3M | 3.7M | 4.7M | 2.4M | |
| Capital Expenditures | 942K | 11.8M | 7.6M | 7.5M | 1.1M | 1.0M | |
| Net Income | (14.0M) | (33.2M) | (61.1M) | (71.2M) | (69.9M) | (66.4M) | |
| End Period Cash Flow | 97.6M | 177.8M | 266.4M | 173.4M | 131.6M | 157.2M | |
| Change To Netincome | 724K | 4.2M | 6.5M | 13.9M | 16.0M | 16.8M |
Achilles Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Achilles Therapeutics's current stock value. Our valuation model uses many indicators to compare Achilles Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Achilles Therapeutics competition to find correlations between indicators driving Achilles Therapeutics's intrinsic value. More Info.Achilles Therapeutics PLC is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers . At this time, Achilles Therapeutics' Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Achilles Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Achilles Therapeutics PLC Systematic Risk
Achilles Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Achilles Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Achilles Therapeutics PLC correlated with the market. If Beta is less than 0 Achilles Therapeutics generally moves in the opposite direction as compared to the market. If Achilles Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Achilles Therapeutics PLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Achilles Therapeutics is generally in the same direction as the market. If Beta > 1 Achilles Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Achilles Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Achilles Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Achilles Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Achilles Therapeutics December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Achilles Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Achilles Therapeutics PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of Achilles Therapeutics PLC based on widely used predictive technical indicators. In general, we focus on analyzing Achilles Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Achilles Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.43 | |||
| Information Ratio | 0.1254 | |||
| Maximum Drawdown | 38.16 | |||
| Value At Risk | (2.78) | |||
| Potential Upside | 3.06 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.66) | Return On Assets (0.27) | Return On Equity (0.44) |
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.